A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis

Guanghan WangDepartment of Dermatology, First Affiliated Hospital of Dalian Medical University, Dalian, China

Xiaojing HuDepartment of Dermatology, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaView further author information

Shixin HanDepartment of Dermatology, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaView further author information

Meijuan ZhouDepartment of Dermatology, First Affiliated Hospital of Dalian Medical University, Dalian, ChinaCorrespondence[email protected]
View further author information

References

Husein-ElAhmed H, Steinhoff M. Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review. J Dermatolog Treat. 2022;33(7):1–4. doi:10.1080/09546634.2022.2089331.
PubMed Web of Science ®Google Scholar
Krueger JG, Wharton KA, Schlitt T, et al. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. J Allergy Clin Immunol. 2019;144(3):750–763. doi:10.1016/j.jaci.2019.04.029.
PubMed Web of Science ®Google Scholar
Ho PH, Tsai TF. Development of bullous pemphigoid during secukinumab treatment for psoriasis. J Dermatol. 2017;44(9):e220–e1. doi:10.1111/1346-8138.13909.
PubMed Web of Science ®Google Scholar
Fatima R, Altorok N. Secukinumab-induced bullous pemphigoid in a patient with psoriatic arthritis. Am J Ther. 2023. doi:10.1097/MJT.0000000000001642.
Google Scholar
Tabatabaei-Panah P-S, Moravvej H, Alirajab M, et al. Association between TH2 cytokine gene polymorphisms and risk of bullous pemphigoid. Immunol Invest. 2022;51(2):343–356. doi:10.1080/08820139.2020.1832113.
PubMed Web of Science ®Google Scholar
Al-Janabi A, Foulkes AC, Mason K, et al. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. Acad Dermatol Venereol. 2020;34(7):1440–1448. doi:10.1111/jdv.16246.
PubMed Web of Science ®Google Scholar